MacroGenics Inc
MGNX1.450USD
-0.130-8.23%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
91.65MMarket Cap
LossP/E TTM
More Details of MacroGenics Inc Company
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.
MacroGenics Inc Info
Ticker SymbolMGNX
Company nameMacroGenics Inc
IPO dateOct 10, 2013
CEOMr. Eric Risser
Number of employees341
Security typeOrdinary Share
Fiscal year-endOct 10
Address9704 Medical Center Drive
CityROCKVILLE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code20850
Phone13012515172
Websitehttps://www.macrogenics.com/
Ticker SymbolMGNX
IPO dateOct 10, 2013
CEOMr. Eric Risser
Company Executives of MacroGenics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. James Karrels
Mr. James Karrels
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
186.80K
--
Mr. William K. Heiden
Mr. William K. Heiden
Independent Chairman of the Board
Independent Chairman of the Board
111.00K
+909.09%
Mr. Edward (Ed) Hurwitz, J.D.
Mr. Edward (Ed) Hurwitz, J.D.
Independent Director
Independent Director
44.07K
+17.30%
Dr. Stephen L. Eck, M.D., Ph.D.
Dr. Stephen L. Eck, M.D., Ph.D.
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
29.38K
--
Mr. Thomas Spitznagel, Ph.D.
Mr. Thomas Spitznagel, Ph.D.
Senior Vice President - Technical Operations
Senior Vice President - Technical Operations
21.40K
+157.36%
Dr. Margaret A. Liu, M.D.
Dr. Margaret A. Liu, M.D.
Independent Director
Independent Director
11.00K
+144.44%
Dr. Ezio Bonvini, M.D.
Dr. Ezio Bonvini, M.D.
Senior Vice President - Research, Chief Scientific Officer
Senior Vice President - Research, Chief Scientific Officer
--
--
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
Mr. Eric Risser
Mr. Eric Risser
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Jeffrey Peters
Mr. Jeffrey Peters
Senior Vice President, General Counsel, Corporate Compliance Officer
Senior Vice President, General Counsel, Corporate Compliance Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. James Karrels
Mr. James Karrels
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
186.80K
--
Mr. William K. Heiden
Mr. William K. Heiden
Independent Chairman of the Board
Independent Chairman of the Board
111.00K
+909.09%
Mr. Edward (Ed) Hurwitz, J.D.
Mr. Edward (Ed) Hurwitz, J.D.
Independent Director
Independent Director
44.07K
+17.30%
Dr. Stephen L. Eck, M.D., Ph.D.
Dr. Stephen L. Eck, M.D., Ph.D.
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
29.38K
--
Mr. Thomas Spitznagel, Ph.D.
Mr. Thomas Spitznagel, Ph.D.
Senior Vice President - Technical Operations
Senior Vice President - Technical Operations
21.40K
+157.36%
Dr. Margaret A. Liu, M.D.
Dr. Margaret A. Liu, M.D.
Independent Director
Independent Director
11.00K
+144.44%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Aug 17
Updated: Sun, Aug 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bellevue Asset Management AG
15.69%
Armistice Capital LLC
9.43%
The Vanguard Group, Inc.
6.67%
Wasatch Global Investors Inc
5.14%
Frazier Life Sciences Management, L.P.
5.02%
Other
58.04%
Shareholders
Shareholders
Proportion
Bellevue Asset Management AG
15.69%
Armistice Capital LLC
9.43%
The Vanguard Group, Inc.
6.67%
Wasatch Global Investors Inc
5.14%
Frazier Life Sciences Management, L.P.
5.02%
Other
58.04%
Shareholder Types
Shareholders
Proportion
Investment Advisor
28.88%
Investment Advisor/Hedge Fund
19.79%
Hedge Fund
18.93%
Private Equity
5.02%
Research Firm
4.22%
Individual Investor
3.34%
Pension Fund
0.11%
Venture Capital
0.02%
Other
19.67%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
334
48.66M
76.98%
-24.24M
2025Q2
349
54.16M
85.84%
-24.12M
2025Q1
365
56.04M
88.82%
-21.64M
2024Q4
367
57.72M
91.98%
-20.16M
2024Q3
367
57.51M
91.64%
-21.39M
2024Q2
370
63.01M
100.47%
-16.59M
2024Q1
368
67.02M
107.12%
-8.36M
2023Q4
353
64.08M
103.25%
-12.72M
2023Q3
352
60.31M
97.24%
-15.19M
2023Q2
356
62.23M
100.48%
-18.91M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bellevue Asset Management AG
9.92M
15.69%
-9.97K
-0.10%
Jun 30, 2025
Armistice Capital LLC
5.96M
9.43%
-336.00K
-5.34%
Jun 30, 2025
The Vanguard Group, Inc.
4.21M
6.67%
-212.88K
-4.81%
Jun 30, 2025
Wasatch Global Investors Inc
3.25M
5.14%
+774.00
+0.02%
Jun 30, 2025
Frazier Life Sciences Management, L.P.
3.18M
5.02%
--
--
Jun 30, 2025
Acadian Asset Management LLC
2.49M
3.94%
+183.05K
+7.93%
Jun 30, 2025
Millennium Management LLC
2.02M
3.19%
+291.61K
+16.91%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.74M
2.76%
-2.76M
-61.25%
Jun 30, 2025
EcoR1 Capital, LLC
1.60M
2.54%
+1.60M
--
Jun 30, 2025
Koenig (Scott)
1.43M
2.26%
+52.83K
+3.85%
Aug 13, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
iShares Micro-Cap ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
Direxion Daily S&P Biotech Bull 3X Shares
0%
SPDR S&P Biotech ETF
0%
Humankind US Stock ETF
0%
Proshares Ultra Russell 2000
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
ProShares Ultra Nasdaq Biotechnology
Proportion0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Invesco Nasdaq Biotechnology ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0%
SPDR S&P Biotech ETF
Proportion0%
Humankind US Stock ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
